Overview

MD1003-AMN MD1003 in Adrenomyeloneuropathy

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day over placebo in the clinical improvement (walking tests) of patients with adrenomyeloneuropathy

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

MedDay Pharmaceuticals SA

Treatments:

Biotin